Secreted by PDAC cells and CAFs, NRG1 activates human epidermal growth factor (HER) signaling in tumor cells, and higher NRG1 and HER3 are linked with poorer survival outcomes.161 Current therapeutic strategies primarily focus on targeting HER3, the fusion partner of NRG1, rather than NRG1 itself. This evidence concerns the gene ERBB3 and neoplasm.